Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Molecular mechanisms associated with multiple sclerosis progression, severity and phenotype

Peter Kosa, Keith Lumbard, Jing Wang, C. Jason Liang, Ruturaj Masvekar, Yujin Kim, Mihael Varosanec, Lori Jennings, Bibiana Bielekova
doi: https://doi.org/10.1101/2022.10.14.22281095
Peter Kosa
1Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Lumbard
2Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research; Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Wang
2Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research; Frederick, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Jason Liang
3Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruturaj Masvekar
1Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yujin Kim
1Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mihael Varosanec
1Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori Jennings
4Novartis Institutes for Biomedical Research; Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bibiana Bielekova
1Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Bibi.Bielekova@nih.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

While current treatments of multiple sclerosis (MS) effectively inhibit formation of focal lesions and relapses, most patients experience progression independent of relapse activity (PIRA). To understand PIRA, we analyzed nine prospectively acquired clinical and imaging outcomes in 176 relapsing-remitting and 215 progressive MS patients and 45 healthy volunteers, along with matched cellular and >5000 protein data in 1,042 cerebrospinal fluid (CSF) samples. Regressing out physiological aging and sex effects identified MS-related processes. Among these, compartmentalized inflammation and its effector mechanisms such as pyroptosis showed the strongest association with MS severity, irrespective of clinical categorization of patients. However, molecular processes affected localization of CNS injury: patients with predominant brain damage had proportionally higher neuroinflammation, while fibrosis and tissue hypoxia were linked to principal involvement of spinal cord. We did not identify inflammation-unrelated neurodegeneration; instead, CNS-related processes were beneficial, such as synaptogenesis. Machine learning-based CSF biomarker models predicted nine clinical and volumetric imaging outcomes in the independent cohort with accuracy exceeding published MS models.

These data show intra-individual diversity of putative disease mechanisms in MS and implicate processes related to compartmentalized neuroinflammation as leading candidate mechanisms of PIRA. Future drug development should include CNS-penetrant anti-inflammatory agents.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This project was also supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N910D00024, Task Order No. 75N91019F00130.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by National Institutes of Health Institutional Review Board. All subjects signed a written informed consent prior to inclusion in the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict-of-interest statement: The authors have declared that no conflict of interest exists.

Data Availability

The datasets generated during and/or analyzed during the current study as well as the custom codes used to perform analyses will be available from the corresponding author after the manuscript has been peer-reviewed and published.

  • Abbreviations

    9HPT
    nine-hole peg test
    AI
    ambulation index
    ARMSS
    age-related multiple sclerosis severity
    BBB
    blood-brain barrier
    BD
    brain damage
    BPFr
    brain parenchymal fraction
    CCC
    concordance correlation coefficient
    CEL
    contrast-enhancing lesion
    CombiWISE
    combinatorial weight-adjusted disability score
    CNS
    central nervous system
    CSF
    cerebrospinal fluid
    DC
    dendritic cell
    EAE
    experimental autoimmune encephalomyelitis
    EBV
    Epstein-Barr virus
    EDSS
    expanded disability status scale
    EMT
    epithelial-mesenchymal transition
    EN
    elastic net
    FDR
    false discovery rate
    FLAIR
    fluid attenuation inversion recovery
    HV
    healthy volunteer
    IPA
    Ingenuity Pathway Analysis
    IPEC
    Instituto de Pesquisa Clinica Evandro Chagas
    IQR
    interquartile range
    lncRNA
    long non-coding RNA
    LP
    lumbar puncture
    MPRAGE
    magnetization-prepared rapid gradient echo
    MRI
    magnetic resonance imaging
    MS
    multiple sclerosis
    MS-DSS
    multiple sclerosis disease severity scale
    MSSS
    multiple sclerosis severity score
    NIH
    National Institutes of Health
    NK cell
    natural killer cell
    NO
    nitric oxide
    OOB
    out-of-bag
    PASAT
    paced auditory serial addition test
    PIRA
    progression independent of relapse activity
    PPMS
    primary progressive multiple sclerosis
    PMS
    progressive multiple sclerosis
    PRR
    patter-recognition receptors
    RF
    random forest
    RFU
    relative fluorescent units
    RMSE
    root mean square error
    ROS
    reactive oxygen species
    RRMS
    relapsing-remitting multiple sclerosis
    SC
    spinal cord
    SDMT
    symbol-digit modalities test
    SNRS
    Scripps neurological rating scale
    SPMS
    secondary progressive multiple sclerosis
    T25FW
    timed 25-foot walk
    T2LL
    T2 lesion load
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
    Back to top
    PreviousNext
    Posted October 17, 2022.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Molecular mechanisms associated with multiple sclerosis progression, severity and phenotype
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Molecular mechanisms associated with multiple sclerosis progression, severity and phenotype
    Peter Kosa, Keith Lumbard, Jing Wang, C. Jason Liang, Ruturaj Masvekar, Yujin Kim, Mihael Varosanec, Lori Jennings, Bibiana Bielekova
    medRxiv 2022.10.14.22281095; doi: https://doi.org/10.1101/2022.10.14.22281095
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Molecular mechanisms associated with multiple sclerosis progression, severity and phenotype
    Peter Kosa, Keith Lumbard, Jing Wang, C. Jason Liang, Ruturaj Masvekar, Yujin Kim, Mihael Varosanec, Lori Jennings, Bibiana Bielekova
    medRxiv 2022.10.14.22281095; doi: https://doi.org/10.1101/2022.10.14.22281095

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Neurology
    Subject Areas
    All Articles
    • Addiction Medicine (227)
    • Allergy and Immunology (502)
    • Anesthesia (110)
    • Cardiovascular Medicine (1234)
    • Dentistry and Oral Medicine (206)
    • Dermatology (147)
    • Emergency Medicine (282)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (530)
    • Epidemiology (10015)
    • Forensic Medicine (5)
    • Gastroenterology (499)
    • Genetic and Genomic Medicine (2449)
    • Geriatric Medicine (236)
    • Health Economics (479)
    • Health Informatics (1638)
    • Health Policy (751)
    • Health Systems and Quality Improvement (636)
    • Hematology (248)
    • HIV/AIDS (532)
    • Infectious Diseases (except HIV/AIDS) (11862)
    • Intensive Care and Critical Care Medicine (625)
    • Medical Education (252)
    • Medical Ethics (74)
    • Nephrology (268)
    • Neurology (2278)
    • Nursing (139)
    • Nutrition (350)
    • Obstetrics and Gynecology (453)
    • Occupational and Environmental Health (535)
    • Oncology (1245)
    • Ophthalmology (375)
    • Orthopedics (133)
    • Otolaryngology (226)
    • Pain Medicine (155)
    • Palliative Medicine (50)
    • Pathology (324)
    • Pediatrics (729)
    • Pharmacology and Therapeutics (311)
    • Primary Care Research (282)
    • Psychiatry and Clinical Psychology (2280)
    • Public and Global Health (4829)
    • Radiology and Imaging (834)
    • Rehabilitation Medicine and Physical Therapy (490)
    • Respiratory Medicine (651)
    • Rheumatology (283)
    • Sexual and Reproductive Health (237)
    • Sports Medicine (226)
    • Surgery (266)
    • Toxicology (44)
    • Transplantation (125)
    • Urology (99)